- Bedoelde u
- mrsa virus
Zoekresultaten - 27 results
Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Alpha- and Delta-dominant circulation: I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021.
study teams (in addition to the named authors) Source: Euro Surveill, Volume 28, Issue 47 (2023) Keywords: Adult BNT162 Vaccine COVID-19 Europe Hospitalization Humans RNA, Viral SARS-CoV-2 Vaccine ...
Humoral and cellular immune correlates of protection against COVID-19 in kidney transplant recipients.
J Transplant, Volume 23, Issue 5 (2023) Keywords: Antibodies, Neutralizing Antibodies, Viral BNT162 Vaccine Breakthrough Infections Cohort Studies COVID-19 Humans Immunoglobulin G Interferon-gamma Kidney ...
Third dose of COVID-19 mRNA vaccine closes the gap in immune response between naïve nursing home residents and healthy adults.
Antibodies, Viral BNT162 Vaccine Breakthrough Infections COVID-19 COVID-19 Vaccines Humans Immunity nursing homes Population Groups RNA, Messenger SARS-CoV-2 Abstract: BACKGROUND: Nursing home residents, ...
Homologous versus heterologous prime-boost COVID-19 vaccination: impact on clinical severity of Omicron among hospitalized COVID-19 patients in Belgium
confirmed by whole genome sequencing and vaccinated with a homologous (mRNA for prime/mRNA for boost) or heterologous (viral vector for prime/mRNA for boost) prime-boost vaccination schedule were included in ...
Homologous and Heterologous Prime-Boost Vaccination: Impact on Clinical Severity of SARS-CoV-2 Omicron Infection among Hospitalized COVID-19 Patients in Belgium
investigated effectiveness of (1) mRNA booster vaccination versus primary vaccination only and (2) heterologous (viral vector-mRNA) versus homologous (mRNA-mRNA) prime-boost vaccination against severe outcomes ...
Safety and immunogenicity of a reduced dose of the BNT162b2 mRNA COVID-19 vaccine (REDU-VAC): A single blind, randomized, non-inferiority trial
I Desombere; Kevin K. Ariën; Maria Goossens Source: PLOS Global Public Health, Volume 2, Issue 12 (2022) Keywords: COVID-19; fractional dose; reduced dose; mRNA vaccination; non-inferiority; SARS-CoV-2 Abstract: ...
Insights From Early Clinical Trials Assessing Response to mRNA SARS-CoV-2 Vaccination in Immunocompromised Patients.
Stéphanie Humblet-Baron Source: Front Immunol, Volume 13 (2022) Keywords: 2019-nCoV Vaccine mRNA-1273 Antibodies, Viral BNT162 Vaccine COVID-19 COVID-19 Vaccines Humans Immunocompromised Host mRNA Vaccines ...
Vaccine effectiveness against onward transmission of SARS-CoV2-infection by variant of concern and time since vaccination, Belgian contact tracing, 2021.
over Bayes Theorem Belgium BNT162 Vaccine Contact Tracing COVID-19 Humans middle aged RNA, Viral SARS-CoV-2 Vaccination Vaccine Efficacy vaccines Abstract: BACKGROUND: During the first half of 2021, we ...
Prevalence of anti-SARS-CoV-2 antibodies in the general population in Belgium: Results of the second data collection (28/09/21-23/02/22)
mRNA vaccine compared to adenoviral-vectored vaccine reduced the risk of being seronegative by 90%. Health Topics: Coronavirus Coronavirus Coronavirus Service: Information sanitaire ...
Prevalence of Anti-SARS-CoV-2 Antibodies and Potential Determinants among the Belgian Adult Population: Baseline Results of a Prospective Cohort Study
chronic disease (OR a 0.22 (95% CI 0.08–0.62)), having received an mRNA-type vaccine (OR a 5.38 (95% CI 1.72–16.80)), and having received an influenza vaccine in 2020–2021 (OR a 3.79 (95% CI 1.30–11.07)). ...